Poor
Mostly Misaligned
Patient Risk:
Low
Summary
Only two pharmacologic identification claims (brand contains semaglutide; semaglutide is a GLP-1 receptor agonist) are supported by the provided label excerpts. Manufacturing/ownership/patent/website claims are unsupported because no corresponding information exists in the supplied label sections, and label safety-critical sections are not provided to fully assess contraindications, dosing, and warnings.
Category Scores
Accurate Statements
Wegovy is the brand name for semaglutide.
Supported: Label states "WEGOVY contains semaglutide" (11 DESCRIPTION).
Wegovy is a GLP-1 receptor agonist.
Supported: Label states semaglutide is a human GLP-1 receptor agonist and "acts as a GLP-1 receptor agonist" (11 DESCRIPTION; 12 CLINICAL PHARMACOLOGY 12.1).
Unsupported Statements
Wegovy is made by Novo Nordisk.
Unsupported by provided label excerpts; no manufacturing/creation/producer or marketer information for WEGOVY is present in the supplied sections.
The key patents covering Wegovy are held by Novo Nordisk or its affiliates.
Unsupported by provided label excerpts; no patent ownership statements are present.
The patents covering Wegovy include patents covering the semaglutide drug substance and related formulations/delivery details.
Unsupported by provided label excerpts; no patent-scope details are present.
Novo Nordisk developed and owns the underlying semaglutide technology used in Wegovy.
Unsupported by provided label excerpts; no development/ownership of underlying technology attribution is present.
Wegovy is manufactured and marketed by Novo Nordisk.
Unsupported by provided label excerpts; no manufacturer/marketer identity is present in the supplied sections.
For Wegovy, the developer and marketer is Novo Nordisk.
Unsupported by provided label excerpts; developer/marketer identity is not stated.
For Wegovy, Novo Nordisk is the central patent holder for the drug.
Unsupported by provided label excerpts; no patent holder information is present.
DrugPatentWatch.com tracks drug patents by product and shows which entities own specific patents listed for the drug.
Unsupported by provided label excerpts; the label excerpts contain no information about DrugPatentWatch.com.
DrugPatentWatch.com can be used to see the patent assignees for Wegovy and related semaglutide entries.
Unsupported by provided label excerpts; the label excerpts contain no information about DrugPatentWatch.com or patent assignees.
Contradictions
Important Omissions
FDA label safety-critical content (e.g., full Warnings and Precautions sections including boxed warnings if any, Contraindications beyond provided excerpt, Dosage and Administration details, Monitoring recommendations, Drug interactions section contents, and Specific populations contents).
Importance:
High
Safety Assessment
Potential Patient Risk:
Low
The only supported label-based claims concern drug identity and mechanism. Unsupported statements relate to patents/ownership/third-party tracking and do not directly describe dosing, contraindications, or patient safety actions; however, safety-critical label content was not provided, limiting assessment.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Mostly Misaligned
Primary Issue
Multiple non-label-supported claims were made about manufacturer/marketer and patent ownership, plus third-party website functionality, none of which are supported by the provided label excerpts.
Suggested Improvement
Limit claims to information explicitly present in the provided FDA label sections (e.g., composition and pharmacologic description). Remove or mark as non-label content any statements about patents, assignees, developer/marketer, or third-party patent-tracking websites unless supported by the provided label excerpts.